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Pain management options for the equine orthopedic patient are limited and can
have harmful systemic effects. Methods of local drug delivery such as intravenous
regional limb perfusion (IVRLP) are able to provide more focal therapy with a decreased
risk of systemic side effects.
The primary goal of the present study was to develop a novel, targeted pain
management approach able to mitigate the complications encountered with systemic
opioid administration. There were two main objectives with respect to elucidating the
usefulness of a butorphanol IVRLP. The first of these was to evaluate the feasibility of
IVRLP to deliver butorphanol to the treated limb, and the second was to develop a
method for evaluating the analgesic efficacy of the procedure.
The findings suggest butorphanol IVRLP is well tolerated, results in measurable
levels of butorphanol in the treated limb and may be of analgesic benefit.
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CHAPTER I
INTRODUCTION
Pain Management in the Horse
Pain management options for the equine patient are limited, and investigations
into novel analgesic protocols have made little progress in comparison to the advances
made in small animal medicine.1,2 Equine patients, particularly those with painful
orthopedic conditions, are at risk of a number of sequelae, not only directly due to the
effects of the drugs used, but also due to the somewhat modest improvements in comfortlevel that are often achieved.1 In addition to the concerns regarding patient welfare,
persistent discomfort results in a depressed patient with a slower rate of healing and a
propensity for catastrophic outcomes such as support-limb laminitis.1 As such, it is
imperative to keep striving for improvement in this area of case management.
Most commonly, painful conditions in horses are treated with systemic nonsteroidal anti-inflammatory drugs (NSAID) such as flunixin meglumine, phenylbutazone,
firocoxib and ketoprofen.1–3 These drugs work by inhibiting the cyclooxygenase (COX)
pathway of the inflammatory cascade and are thus most appropriate in cases where pain
is secondary to an inflammatory process.1 While considered generally efficacious,
NSAID therapy is not without consequence.1 Inhibition of the COX pathway inhibits
production of prostaglandin F2α, a potent inflammatory mediator.1 However, COX
inhibition can also reduce the production of other, protective prostaglandins in the
gastrointestinal and urinary tracts.1,4 As a result, consequences of their use include
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gastrointestinal ulceration and necrosis and renal papillary necrosis – sequelae that can
become life-threatening.1,4 Development of more selective NSAID has led to improved
safety profiles for these medications compared to the more traditional, non-selective
varieties.5 However, while generally considered the “safe” NSAID, more selective drugs,
such as firocoxib, have also been shown to have similar complications when used for
prolonged periods or in combination with non-selective inhibitors.6,7
Another class of analgesics commonly used in both human and veterinary patients
is the opioids.8 Opioids work by binding to opioid receptors, of which there are three
main types – mu, kappa and delta – present both in the central nervous system and
peripheral tissues.9–15 They have both analgesic and anti-inflammatory effects in horses,
making them an attractive option for the alleviation of several causes of pain.9–12
Furthermore, certain opioid receptors have been found to be upregulated in inflamed
synovium, making opioid drugs with an affinity for these receptors an excellent choice
for orthopedic pain arising from synovial insult.14 Additionally, a further benefit of
opioids is that they can be administered via a constant-rate infusion (CRI), providing
continuous, regulated doses that result in consistent pain management.10,16 Despite these
benefits, systemic use of opioids in horses is associated with significant disadvantages.8
When used alone, opioids are reported to cause dangerous and unpredictable central
nervous system excitation, although this is uncommonly seen in the clinically painful
patient.10 A more commonly cited reason for avoiding opioid use in equine patients is the
resulting reduction in gastrointestinal motility that is considered to put the patient at an
increased risk for colic.8–11 The negative gastrointestinal effects of opioids have been
predominantly attributed to mu receptor agonism, such as with morphine, a pure mu
agonist.9,11,17,18 Butorphanol, by comparison, is an opioid that is typically more readily
2

available and widely used in equine practice.2,19 Its analgesic effects following systemic
administration in adults have been well studied, and it is also an effective, well-tolerated
option for young foals.2,11,21–31 Butorphanol is unique in that is it is considered an opioid
agonist-antagonist, having predominant activity at kappa receptors and some degree of
mu receptor antagonism.16,17,21 Its reduced mu activity is thought to explain the less
significant impact it has on gastrointestinal motility in comparison to other opioids such
as morphine.16,17,21 Additionally, the kappa agonism has been thought to offer a further
advantage, as kappa agonist use has been shown to be of benefit in human and animal
joint disease models.30,31
Given the problems associated with NSAID and systemic opioid use, other drug
classes have been investigated for their analgesic benefits, including alpha-2 adrenergic
agonists, local anesthetic agents, dissociative anesthetics, or some combination of
these.2,4,32,33 Alpha-2 agonists, such as xylazine and detomidine, provide potent analgesia
in addition to their sedative effects, but are not always an appropriate choice given the
sedation and ataxia they induce.34 Lidocaine is a commonly utilized local anesthetic agent
that, when delivered as a CRI, can provide both analgesic and anti-inflammatory
benefits.2 However, its administration requires maintenance of a patent catheter, as well
as close monitoring to avoid overdose which may result in ataxia or sudden collapse –
neither of which is desirable, particularly in the case of an orthopedic patient.2,33 Lastly,
ketamine, a dissociative anesthetic, has been utilized at sub-anesthetic doses either alone
or in combination with one or more of the aforementioned drug classes to provide
analgesia.32 Uncommonly used on its own due to its short duration of action, its use in
combination with opioids, local anesthetics or alpha-2 agonists (i.e. such as in a tri- or
penta-fusion CRI) has been reported to provide significant pain relief.6,32 However, this is
3

associated with the sequelae of the other medications with which it is administered – such
as delayed gastrointestinal motility, ataxia, etc. – and thus also not an ideal choice for
many cases. Other analgesic options available for use in horses include gabapentin,
tramadol and paracetamol, however, their use is much less frequent and less well
described in the literature so will not be discussed in any further depth here.2,35
Due to the clear downsides of these systemically-administered options, alternate
routes of analgesic drug delivery have been investigated. These include direct delivery
via soaker catheters or intra-articular injection, use of transdermal patches, or epidural
administration in either a bolus dose or via an indwelling catheter.1,2,35,36 The benefit of
these local therapies is the elimination or reduction of the sequelae seen with systemic
administration. However, each of these brings its own set of shortcomings: soaker
catheters are of limited use due to an inability to maintain patency and the quantity of
drug needed; intra-articular injection requires repeated puncture of the synovial
environment, risking synovial flare or sepsis; transdermal patches are variably efficacious
and often not cost effective; and epidural catheters are only of benefit for hindlimb
conditions, must be meticulously managed, and carry a risk of ascending infection.1,2,35–39
More recently, investigation into the use of local limb perfusions as a route of analgesic
drug administration has garnered interest.40,41 This route involves administration of a
small volume of drug to a particular region of the body that is isolated by way of a
tourniquet.42 To date, the predominant choice for such perfusions has been local
anesthetics, however there has been recent interest in utilizing this approach to administer
other analgesics, such as opioids.40–42
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Regional Limb Perfusion
Due to concerns regarding the efficacy, safety and cost associated with systemic
medication administration to horses, several routes of local drug delivery have been
developed.43 These routes include direct intra-synovial or intra-thecal injection,
impregnated materials placed into the site of interest, or local perfusions via the
vasculature or medullary cavities in the vicinity.43,44 Of these, intravenous regional limb
perfusion (IVRLP) is perhaps the most common method utilized in horses.42,44,45
IVRLP is a method by which a drug solution, known as the perfusate, is
administered into a local area that is isolated from the rest of the body by some form of
tourniquet.44 In horses the technique is restricted to use in the distal extremities, as these
are the only regions that can be isolated by tourniquet application.43 Once the tourniquet
is placed, a prominent vessel distal to the tourniquet is used to administer the perfusate to
the region.44 The technique relies on both concentration and pressure gradients, created
by a highly concentrated perfusate and the increased intravascular pressure created by the
tourniquet, to force diffusion of the drug into surrounding tissues.44 The primary benefit
of this route of administration is the ability to use far lower doses than would be needed
to achieve an equivalent concentration in the area if the drug were to be given
systemically.42 Often, drug concentrations that can be reached via IVRLP would be
impossible or unsafe to achieve with systemic administration.46,47 In addition to this
improved safety profile, an important secondary benefit is the reduced cost associated
with the lower doses used, and generally shortened duration of therapy required.42,44
To date, IVRLP in horses has predominantly been used to deliver high
concentrations of antimicrobials to the distal limbs of horses to treat a variety of
conditions, such as synovial sepsis and contaminated wounds, as well as for prophylactic
5

perioperative antibiotic delivery.42 Antimicrobial IVRLP has been shown to result in
concentrations in the target tissues far exceeding the necessary minimum inhibitory
concentrations needed for a variety of agents.43 This application has unquestionably
improved the outcome of many complicated cases, by speeding recovery, reducing the
risk of sequelae, and drastically reducing the cost of treatment.43,44 However, this
technique is not limited to antimicrobial delivery.40,41,44,46,48,49 It has also been utilized to
deliver anti-inflammatory, anesthetic and analgesic agents in an attempt to augment
traditional pain management protocols.7,12,13 Although infrequently reported in equine
patients, the administration of local anesthetic agents via IVRLP is routine in both bovine
and human medicine.40,44,50 IVRLP with dimethyl sulfoxide has also been used
successfully for anti-inflammatory therapy of septic distal limb conditions in horses, and
recently interest has developed in utilizing this route of administration for opioid
delivery.41,48
The use of IVRLP for equine analgesia is an attractive concept, as this could offer
a means by which to provide targeted pain relief, while simultaneously avoiding the
complications associated with systemic analgesic administration. In particular, opioids
seem to be ideal candidates for IVRLP, given the need to avoid their significant systemic
side effects. Additionally, they cause neither the perivascular irritation reported with
NSAID administration, nor the complete desensitization that occurs with local
anesthetics. Hunter et al. (2015) were the first to investigate opioid IVRLP in horses.
They evaluated this route of administration for morphine, a pure mu opioid receptor
agonist, as it had previously been reported that mu receptors are upregulated in
osteoarthritic equine joints.14,41 They were able to show that morphine IVRLP in the
forelimbs of horses resulted in measurable levels in the synovial fluid of the middle
6

carpal joint, although the clinical benefit this provided was not investigated.41 However,
morphine has been reported to cause a profound decrease in motility in several species,
which has been attributed to its pure mu activity.9,11,17,18 In comparison, butorphanol has
been associated with less severe sequelae and may thus offer a good alternative for opioid
IVRLP.17 Its reduced mu activity is thought to explain its lesser impact on gastrointestinal
motility.16,17,21 This antagonist activity at mu receptors also suggests the benefits of
butorphanol use must stem from a mechanism different than those proposed for
morphine. While the kappa receptor distribution and effects are not as well understood in
horses, peripheral kappa receptors have been identified and kappa agonists have been
shown to be of benefit in joint disease models in other species.30,31,51 Specifically, local
kappa agonist use reduces intra-articular inflammation in rats, and in human arthritis
patients has demonstrated anti-arthritic effects and stimulated upregulation of kappa
receptors, suggesting a beneficial positive feedback effect.30,31 The present study aimed to
elucidate the usefulness of butorphanol for IVRLP. If effective, this would offer the
equine practitioner an additional tool for multimodal analgesia in patients suffering from
painful distal limb conditions.
Antinociceptive Testing
When investigating the use of a novel analgesic IVRLP, there must be a means by
which to objectively assess the pain modulation it provides. This presents a challenge,
however, as testing analgesic efficacy can be difficult in horses, due to their temperament
and potentially violent responses to pain.26 In clinical cases where the patient displays
clear signs of discomfort, it may be relatively easy to identify an improvement in their
clinical picture, and objective scoring systems such as the equine pain scoring system,
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lameness scales or a lameness locator can be used.52,53 However, identifying an effect in a
healthy, non-painful subject, such as those used in drug studies, may be more difficult.
The most commonly reported method of assessing pain and responses to analgesia
in animals is nociceptive testing, also known as analgesiometry.26,54 It involves the
application of a quantifiable noxious stimulus until a behavioral or physiological
avoidance response is elicited, at which point application of the stimulus is
terminated.26,53 The point at which the animal shows an avoidance response is termed the
animal’s nociceptive threshold.26,55 For safety reasons, a pre-set end-point is determined
prior to testing, beyond which the animal is considered to have no response and no
further stimulus is applied.26 Several things can influence nociceptive thresholds,
including analgesic administration or abnormal physiological responses to pain such as
hyperalgesia (increase in response to pain and thus decreased thresholds) due to
sensitization or hypoalgesia (reduction in response to pain and thus increased thresholds)
due to habituation.26 When assessing the efficacy of a particular analgesic, if the drug is
effective this should be manifest as an increase in this threshold (i.e. it should require
more noxious stimulus to achieve a response).26,55
Several different types of noxious stimuli have been utilized in nociceptive testing
of horses, including thermal, electrical and mechanical means.26,53 Thermal methods have
included such things as cutaneous warming via heat lamps or heating via direct contact of
thermodes with tissues.26,56 Electrical stimulation is usually created via transcutaneous
electrodes or via implantation of electrodes along a nerve of interest.57,58 Mechanical
stimuli are generally some form of pressure application, either with a hand-held
algometer or utilizing a pneumatic cylinder that transmits pressure via an attached blunt
ended pin.26 Mechanical methods tend to be easier to instrument consistently and have
8

safer end-points than thermal or electrical methods, with fewer significant complications
(i.e. minor skin bruising versus burns or violent reflex responses).26 A recent study
reported excellent validity of each of three types of stimuli – citing good sensitivity,
specificity and reliability.55 However, when ranked with respect to efficacy for testing the
distal limb, mechanical testing was deemed the most sensitive, followed by thermal and
electrical.55 It is also argued that mechanical testing is the most appropriate with respect
to horses, given that most nociceptive stimuli equine patients experience are mechanical
(e.g. weight bearing, blunt trauma, lacerations, etc.).55
Nociceptive threshold testing has previously been used to evaluate the efficacy of
analgesic administration in horses.23,59 It has been shown that thermal and mechanical
nociceptive thresholds increase in response to systemic administration of butorphanol,
supporting its use as an analgesic.23,26 Mechanical nociceptive testing has also been used
to investigate the consequences of adding of a local anesthetic to an antibiotic IVRLP.40
Addition of mepivacaine hydrochloride to an amikacin IVRLP resulted in increased
MNT, suggesting an analgesic effect.40 It was also shown that addition of this agent did
not significantly affect the concentrations of antibiotic achieved, nor its antimicrobial
efficacy – important considerations if planning to use a combined IVRLP.40 Based on
these findings, it was expected that mechanical nociceptive testing would be an
appropriate tool to assess the analgesic benefit of butorphanol IVRLP.
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CHAPTER II
METHODOLOGY
Objectives
The present study had two objectives with respect to elucidating the usefulness of
butorphanol IVRLP. The primary objective was to evaluate the feasibility of IVRLP to
deliver butorphanol to the radiocarpal joint of the treated limb. It was hypothesized that
cephalic IVRLP with 10 mg of butorphanol would result in measurable concentrations in
the radiocarpal joint for several hours. The second objective was to develop a method for
evaluating the analgesic efficacy of the procedure. It was hypothesized that butorphanol
IVRLP would result in a significant increase in mechanical nociceptive thresholds
(MNT) in treated limbs versus untreated control limbs, consistent with an analgesic
effect.
Animals
Six healthy adult horses (median weight 480 kg; range 422 - 560) including two
mares and four geldings (four American Quarter Horses and two Arabians) were used in
the study. All horses were deemed healthy following physical examination. Each horse
was deemed sound (grade 0/5) in the forelimbs, according to the American Association of
Equine Practitioner (AAEP) 5-point lameness scale, and showed no response to bilateral
carpal flexion.60 No horse had any evidence of superficial skin injury on the limbs, and
all were confirmed to respond to pressure applied over the dorsal distal limb. No horse
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received opioids in the two months prior to inclusion in the study. Horses were
hospitalized 24 hours prior to their respective sampling day and housed in box stalls for a
total of five days before returning to usual turnout. Procedures were performed with the
approval of the Institutional Animal Care and Use Committee.
Intravenous Regional Limb Perfusion and Sample Collection
The limb to be treated was assigned using a masked random draw. The other
forelimb was left untreated as a control for MNT testing, as described below. Prior to
sedation for IVRLP, baseline (T0) blood and synovial samples were collected and
baseline MNT testing was performed. Prior to IVRLP administration and each sample
collection, the cephalic vein, jugular veins and dorsal aspect of the carpus were
aseptically prepared using 4% chlorhexidine gluconate scrub and 70% isopropyl alcohol.
Blood samples were collected into 10 mL red top (no additive) glass tubes using standard
vacutainer equipment. Synovial fluid samples (1 mL) were collected from the radiocarpal
joint using sterile technique and a 20-gauge, 1.5 cm hypodermic needle via a dorsolateral
approach before being transferred to a 3 mL purple-top (EDTA) glass tube.
Following collection of the T0 samples, the horses were sedated with detomidine
hydrochloride (5 mg total or 0.009 - 0.012 mg/kg intravenously [IV]). One 10.6 cm wide,
30.5 cm long rubber tourniquet (Latex Esmark Bandage; Jorgensen Laboratories, Inc.,
Loveland, CO) was placed as tightly as possible around the radius of the selected limb,
extending proximally from the level of the chestnut. Two gauze rolls were placed on the
medial and lateral aspect of the limb under the tourniquet to improve vascular
compression. IVRLP was then performed using sterile technique with a 23-gauge, 1.91
cm butterfly catheter with the needle directed distally in the cephalic vein, distal to the
11

tourniquet and proximal to the radiocarpal joint. The perfusate (10 mg butorphanol
tartrate diluted to a total volume of 30 mL with sterile 0.9% NaCl) was administered by
hand over three minutes. The needle was removed following infusion and the site was
covered with a temporary bandage of gauze and inelastic tape for the duration of the
perfusion. The horse was left to stand with the tourniquet in place for 30 minutes, with
monitoring of limb movement and supplemental sedation with xylazine boluses (50 - 200
mg or 0.12 - 0.36 mg/kg IV) administered if excessive movement (i.e. repeated placing or
walking) was observed. Subtle swaying or shifting in the hind end did not prompt
additional sedation. All perfusions were video-recorded to allow subsequent movement
analysis.
Immediately following tourniquet removal, blood and synovial fluid samples were
collected, as described above, at 0.5, 1, 2, 4 and 6 hours after conclusion of the IVRLP.
All time points were in relation to the conclusion of the IVRLP perfusate administration –
for example, the 0.5-hour sample was taken immediately after tourniquet removal, which
was 0.5 hours (or 30 minutes) after conclusion of the IVRLP administration. MNT testing
was also repeated at these intervals, as described below. Between collections, the
sampled carpus was bandaged with a sterile rolled gauze and elastic bandage to keep the
area free from contamination. Following the final synoviocentesis, 500 mg of amikacin
was administered intra-articularly and each horse received a single dose of
phenylbutazone (4.4 mg/kg IV once).
Blood and synovial fluid samples were centrifuged at 3500xg for five minutes
within 30 minutes of collection, and aliquots of each were transferred to 3 mL red top (no
additive) glass tubes to be subsequently frozen at -80 °C until analysis. The stability of
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the drug in frozen synovial samples was verified in a separate method validation project
prior to the study (unpublished data).
Mechanical Nociceptive Threshold Data Collection
Prior to IVRLP, baseline MNT measurements were obtained from both treated
and control limbs. Three stimulation sites were tested: the dorsolateral aspect of the middiaphysis of the third metacarpal bone; the dorsolateral aspect of the mid-diaphysis of the
proximal phalanx; and the dorsal coronary band. The same handheld pressure algometer
(FPK 10 Wagner Pain Test Algometer; Wagner Instruments, Greenwich, CT), with a 6.5
mm diameter flat steel probe with rounded edge and stimulation area of approximately 33
mm2, was used for all measurements and all were performed by the same investigator.
The range of the algometer was 0.0 - 5.0 kg/cm2 and the maximum of this range was used
as the safety end point (i.e. pressure application was discontinued if this reading was
reached, even if there was no response) in order to avoid tissue damage. Each stimulus
was performed as a ramped pressure, until the horse expressed the behavioral avoidance
reaction of removing the leg from the probe, or until the safety end point was reached,
both of which terminated the stimulus and was recorded as the MNT. Two repeated MNT
measurements were taken approximately 15 seconds apart and averaged for analysis.
Horses were blindfolded prior to testing. Pre- and post-sedation measurements were taken
three minutes before and after administration of sedation, respectively, and prior to
tourniquet application. The remaining measurements were taken immediately following
tourniquet removal (0.5 hour following IVRLP) and at 1, 2, 4 and 6 hours following
IVRLP. All MNT measurements were collected prior to synovial sampling.
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Post-Procedure Monitoring
The horses were evaluated for attitude and comfort level hourly and received
physical exams every four hours, including enumeration of manure piles, the day of the
procedure. These were subsequently performed every four and eight hours, respectively,
for the four additional days of stall rest. Each horse was also assessed and graded
according to the AAEP lameness scale by the same investigator once daily, after which
the injection and synoviocentesis sites were evaluated for swelling. This investigator was
not blinded to the treated limb; however, they did not review this information prior to the
assessment and was not aware of the MNT or butorphanol analysis results. Once returned
to pasture, the horses were evaluated for attitude and comfort once daily for an additional
week.
Sample Analysis
Butorphanol was extracted from serum and synovial fluid samples by a solidphase extraction (SPE) procedure. Samples were first prepared for analysis by vortexing
with acetonitrile for protein precipitation. Waters Oasis® HLB cartridges were
conditioned with approximately 5 mL of optima grade methanol, followed by
approximately 5 mL of optima grade water. Samples were then passed through the
cartridges at approximately 0.5 mL/min. The SPE cartridge was washed with 5 mL of
optima grade water and allowed to dry for 10 minutes under vacuum. The butorphanol
was then eluted from the cartridge with 4 mL of methanol containing 2% formic acid.
Once the samples were eluted from the SPE cartridge, they were evaporated under
nitrogen gas in a 55°C water bath. The samples were reconstituted to 2 mL with optima
grade methanol and analyzed by Liquid Chromatography coupled to Tandem Mass
Spectrometry (LC-MS/MS).
14

Chromatographic separation was performed using an Agilent 1260 Infinity High
Performance Liquid Chromatograph equipped with an Agilent Xorbax Eclipse Plus C18
(2.1 x 50 mm) 1.8 µm analytical column at 40°C for respectable peak resolution. Optima
grade water and methanol with the addition of 0.1% formic acid and 5 mM ammonium
formate were used as mobile phases with a 5 µL injection volume. The HPLC was
coupled to an Agilent 6360 Triple Quadrupole Mass Spectrometer. The samples were
analyzed using positive electrospray ionization. The following mass spectrometer
conditions were used: sheath gas temperature, 300°C; drying gas temperature, 350°C;
sheath gas flow, 11 L/min; nebulizer pressure, 40 psi; and capillary voltage, 4000 volts.
Multiple reaction monitoring transitions included 328.2 to 310.2 for quantitation, and
328.2 to 157.0 and 328.2 to 56.1 for qualitative purposes. Data collected from the LCMS/MS was assessed using MassHunter B.04 software from Agilent. Based on the
aforementioned method validation study, the limits of detection and quantification for the
described method were 0.05 ng/mL and 0.15 ng/mL, respectively.
Statistical Analysis
Initially, linear mixed models were used to assess the effect of time on
concentration of butorphanol in synovial fluid and serum. However, the models did not
meet the assumptions of normality and homoscedasticity. Consequently, a method similar
to the non-parametric Friedman’s test was used. Synovial and serum values were first
ranked using PROC RANK in SAS for Windows 9.4 (SAS Institute, Inc., Cary, NC) and
then analyzed by linear models using PROC MIXED in SAS for Windows 9.4. Time and
horse identity were the fixed effects.
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The effect of site, treatment, and time on pain MNT was assessed by linear mixed
models using PROC MIXED in SAS for Windows 9.4. The initial model included site,
treatment, time and all two-way interactions. Horse was included as a random effect to
address the measure of pain threshold at multiple sites in each horse. To address the
repeated measures over time, horse by treatment by site was the subject of a repeated
statement with a spatial power covariance structure. If after fitting the model an
interaction term was not significant, it was removed. This was repeated until only fixed
effects and significant interaction terms remained in the model. Using a similar model,
but replacing treatment with synovial concentrations of butorphanol, mixed model linear
regression was used to assess the association of pain threshold and synovial
concentrations of butorphanol in treated horses. As above, horse was included as a
random effect and horse by site was the subject of a repeated statement with a spatial
power covariance structure.
In the case of a significant fixed effect in the models, differences in least squares
means among variable levels were accessed using the SIMULATE option to adjust pvalues for multiple comparisons. The distribution of residuals was evaluated to assess if
the assumptions of normality and homoscedasticity had been met for all models. An
alpha level of 0.05 was used to determine statistical significance.
To assess the degree of variation between the two measurements of MNT made at each
assessment, the coefficient of variation using the logarithmic method was calculated.61,62
Briefly, the data were first log transformed. For each measurement pair, the square root
of the mean within-pair variance was calculated to provide the within-pair standard
deviation. The coefficient of variation was then calculated by taking the antilog of the
standard deviation and subtracting 1.
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CHAPTER III
RESULTS
IVRLP and MNT procedures were well tolerated by all horses. IVRLP was
successful in 5/6 horses, yielding detectable levels of butorphanol in synovial fluid
(Figure 1A). In one horse, no butorphanol was detected in the radiocarpal joint of the
treated limb at any time point, and no systemic levels were detected until two hours postperfusion (T2). As such, data from this horse were excluded from further analysis.
Butorphanol Concentrations
Butorphanol was not detected in any baseline (T0) synovial fluid samples.
Measurable concentrations of butorphanol were achieved in the radiocarpal joint of all
horses, with the exception of the aforementioned exclusion. In 4/5 horses with detectable
levels, the concentration was highest in the sample collected 30 minutes after perfusion
(T0.5) and subsequently decreased at each additional sampling. In one of the five horses,
the highest concentration was measured at one hour (T1) post-perfusion and subsequently
declined. Synovial concentrations remained significantly above baseline until the fourhour time point (T4) (p ≤ 0.017), at which point the differences were no longer
significant (p ≥ 0.767). The overall mean peak synovial butorphanol concentration was
9.47 ng/mL ± 12.00 ng/mL SD. Butorphanol was no longer detectable by two hours postperfusion in 2/5 horses, by four hours in two of the remaining three horses and by six
hours in the last horse.
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No butorphanol was measured in any serum samples collected prior to IVRLP.
Butorphanol was detectable in the serum of 4/5 horses at 30 minutes post-perfusion
(T0.5), and 5/5 horses by one-hour post-perfusion (T1) (Figure 1B). Serum
concentrations remained significantly above baseline until the two-hour time point (T2)
(p ≤ 0.016), at which point the differences were no longer significant (p ≥ 0.518). The
overall mean peak serum butorphanol concentration was 3.89 ng/mL ± 3.29 ng/mL SD.
Butorphanol was no longer detectable in the serum of any horse by six hours postperfusion.
Mechanical Nociceptive Threshold Testing
Mean MNT values are provided in Table 1. MNT values were not significantly
different among the three testing sites (p = 0.955); however, there was a significant time
by treatment interaction (p = 0.022). No significant differences were detected between
control and treated limbs prior to IVRLP (p = 0.999). No significant differences (p >
0.944) were found between treated and control limbs following IVRLP, with the
exception of one-hour post perfusion (T1), at which point the MNT of the control limbs
were higher than that of treated limbs (p = 0.047) (Figure 2). The coefficient of
variability for these repeated measures was 0.18.
When evaluated with a linear regression model accounting for the effect of time, a
positive association between synovial butorphanol concentration and MNT was found (p
= 0.003). More specifically, for each 1 ng/mL increase in synovial concentration there
was a corresponding 0.067 kg/cm2 increase in MNT.
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Clinical Examination and Complications
All vital parameters remained within normal limits throughout the hospitalization period.
Gastrointestinal borborygmi and manure output remained regular and consistent for all
horses throughout the period of hospitalization. No signs of gastrointestinal pain or
inappetence were observed. All horses remained sound in the forelimbs (grade 0/5 on the
AAEP lameness scale) for the duration of the hospitalization period. Two horses
developed mild swelling of the perfusion site and two developed mild swelling over the
synoviocentesis sites in the first two days following perfusion but remained sound and
improved with hydrotherapy and wrapping prior to turnout. No lameness or swelling was
seen during the week while monitored at pasture.
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Mean ± SD MNTs (in kg/cm2) in control limbs vs. limbs treated with

Table 1

butorphanol IVRLP in the five horses with measurable synovial butorphanol
concentrations following IVRLP.
Third Metacarpal
Time

Treated

Control

Proximal Phalanx
Treated

Control

Coronary Band
Treated

Control

T0

3.09 ± 1.15 2.86 ± 1.71 3.39 ± 1.16 3.02 ± 1.70 3.11 ± 1.14 2.87 ± 1.68

T0.5

4.61 ± 0.73 4.13 ± 1.29 4.25 ± 1.68 4.06 ± 1.34 4.56 ± 1.00 3.80 ± 1.35

T1

3.01 ± 0.91 3.91 ± 1.21 3.09 ± 1.89 4.09 ± 0.86 2.95 ± 1.39 4.39 ± 0.84

T2

3.48 ± 2.08 3.94 ± 1.49 3.15 ± 1.75 3.58 ± 1.88 3.44 ± 1.80 3.61 ± 1.54

T4

2.68 ± 0.82 3.29 ± 1.29 2.70 ± 1.43 3.06 ± 1.32 2.49 ± 1.00 2.99 ± 1.35

T6

2.82 ± 1.61 3.56 ± 1.53 2.40 ± 1.73 3.36 ± 1.61 2.75 ± 1.52 3.20 ± 1.73

Testing performed at: the dorsolateral aspect of the mid-diaphysis of the third metacarpal
bone; the dorsolateral aspect of the mid-diaphysis of the proximal phalanx; and the dorsal
coronary band.
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Figure 1.

Radiocarpal synovial fluid butorphanol concentration following butorphanol IVRLP in six healthy, standing sedated

horses.
A. Radiocarpal synovial fluid butorphanol concentrations. B. Serum butorphanol concentrations. Synovial concentrations for
horse 5 were below the level of detection for the methodology used and, as such, this horse was subsequently removed from further
analysis.
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Figure 2.

Mean mechanical nociceptive thresholds (MNTs) in limbs treated with butorphanol IVRLP versus untreated control

limbs.
Means shown are of the 5 horses in which IVRLP was successful. A. Mean MNT at the level of the third metacarpal (MC3). B.
Mean MNT at the level of the first phalanx (P1). C. Mean MNT at the level of the coronary band (CB).
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CHAPTER IV
CONCLUSIONS
Discussion
Cephalic IVRLP resulted in quantifiable concentrations of butorphanol within the
synovial fluid of the radiocarpal joint. Furthermore, synovial butorphanol concentrations
were positively associated with an increased MNT. All horses included in the analysis
achieved measurable synovial butorphanol levels within 30 minutes following perfusion
and levels remained measurable for two to four hours.
The duration of measurable synovial butorphanol concentrations observed in the
present study is consistent with expectations based on the short plasma half-life reported
following intravenous and subcutaneous administration of the drug.21 This duration is
also similar to that of synovial morphine concentrations reported following morphine
IVRLP.41 While it could be argued that this short duration limits the use of this modality
for ongoing pain management, an interesting consideration would be what concentrations
may be achieved in the surrounding soft tissues following IVRLP. The half-life of
butorphanol following subcutaneous administration has been reported to be longer than
that following intravenous administration.21 Given the degree of extravascular diffusion
that occurs with IVRLP, it is expected that the subcutaneous tissues may act as an
effective depot site and maintain sustained butorphanol concentrations in the treated
region.63 This may impart an additional benefit of IVRLP over systemic or intra-articular
use in cases of distal limb surgery or injury, which is likely to be underestimated by
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studies limited to sampling synovial fluid only. Further investigation of the
concentrations achieved in the soft tissues of the distal limb following butorphanol
IVRLP is warranted.
The synovial fluid concentrations achieved in the present study were highly
variable, and it is unknown whether the concentrations achieved would be clinically
relevant. This variability is a common finding in IVRLP studies.63,64 It has been
speculated that this occurs due to inherent anatomical or physiological differences
between horses, varying efficacy of the procedure, or sample collection issues.64 Perhaps
the most commonly cited reason for variability is poor tourniquet efficacy.64,65 Based on
the fact that four horses had serum butorphanol levels at the time of tourniquet removal
(T0.5), it is considered likely that leakage under the tourniquet occurred and the IVRLP
technique used could be improved. Very little consensus has been reached regarding the
specifics of how IVRLPs should be performed, which limits direct comparisons between
studies and the ability to identify sources of variability. There is continued debate
concerning the ideal technical aspects of the procedure (e.g. tourniquet type and number,
perfusate volume, perfusion time, etc.) and, to date, the available data are largely
equivocal.44,47,63,64,66–69 The IVRLP procedure performed in the present report was
intended to reproduce that which may be easily performed by the general practitioner and
attempts were made to ensure consistency of the IVRLP procedure and sample collection
between horses. It is possible that use of a different methodology may have reduced the
variability of the results, but the literature suggests variability is likely regardless of the
procedure used. Knowing this degree of variability is likely, follow-up studies should
ensure adequate subject numbers.
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When considering a novel drug for use in IVRLP, an objective method for
assessing its efficacy is needed. With respect to antimicrobial IVRLP this is relatively
straightforward and can be achieved by comparing the concentrations reached with
known minimal inhibitory concentrations or the effect of such levels on microbial
growth.40,42,44,45,70 With respect to an analgesic IVRLP, however, there is no clear target
concentration. Previous nociceptive studies have shown intravenous butorphanol
administration imparts an analgesic benefit when administered at a dose of 0.1 mg/kg (50
mg in an average 500 kg horse).23,71 A pharmacokinetic study of butorphanol
administration in horses have shown that a single dose of butorphanol at this dosage
resulted in plasma concentrations > 100 ng/mL, much higher those achieved within
synovial fluid in the present study.28 However, when administered as a constant-rate
infusion, the mean plasma concentration achieved was 29 ng/mL, a concentration similar
to that seen in the synovial fluid in the present study.28 It is also of note that the same
study evaluated the severity of gastrointestinal and locomotor side-effects following these
doses, finding significantly less severe effects in the constant-rate infusion group.28 A
similar pattern of less severe side-effects was also reported in association with lower
plasma concentrations achieved following subcutaneous administration versus
intravenous administration.21 While it is tempting to try to draw conclusions based on
these studies, how these systemic concentrations compare to those required locally is
unknown. Nociceptive testing was performed concurrently in the present study, in
anticipation that this could be used to identify differences in thresholds between treated
and untreated limbs, as well as a relationship between the concentrations reached and the
degree of threshold increase. Of the various analgesic testing techniques, mechanical
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nociceptive testing was chosen as it has been reported to be the most reliable and
appropriate, the argument being that most nociceptive stimuli that equine patients
experience are mechanical (e.g. weight bearing, blunt trauma, lacerations, etc.).26,53,55
Similar MNT testing has been used to evaluate systemically-administered analgesics,
including butorphanol, as well as the efficacy of a local anesthetic IVRLP.23,40,59 As
hypothesized, the present study identified a significant positive association between
synovial butorphanol concentration and MNT, suggesting that both this testing
methodology and route of administration for distal limb analgesia may have merit.
However, due to the relatively small sample size, there was insufficient data to make
meaningful comparisons between treated and control limbs at a particular time point or
between particular synovial concentrations and MNT changes. Furthermore, the
necessary use of sedatives for IVRLP further complicated the analysis, given that alpha-2
agonist sedative drugs have also been shown to alter MNT responses.59 All horses were
seen to have a dramatic increase in MNT of both treated and untreated control limbs
following sedation, which likely affected the ability to identify subtle changes in
nociception between limbs. While sedation inevitably confounds the interpretation of
results, it is required for safe and effective IVRLP and should have affected both the
treatment and control limbs to the same degree, rendering comparisons still relevant.
Additional studies with a larger sample size are necessary to more specifically investigate
these effects and hopefully identify a specific intra-synovial concentration associated
with an analgesic effect, thereby providing an appropriate target concentration.
An interesting finding in the present study was that the only significant difference
identified between treated and control limbs was the increased MNT in the control limb
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versus the treated limb at one-hour post-perfusion. This result is counter to what would
be expected. However, after review of the timing, it is suspected that this represents a
period of hyperalgesia following tourniquet removal. Tourniquets are known to cause
discomfort in human patients, such that their use is predominantly restricted to
anesthetized patients.72–74 Similarly, their use in minimally-sedated horses can result in
violent responses, necessitating the use of sedation prior to IVRLP.44 Tourniquet release
is reported to cause pain in human patients, which is also suspected in equine patients
based on their repetitive limb movements after removal.73 It is possible that, in
conjunction with small sample size, this unexpected effect on MNTs may have masked
the analgesic effects expected from the butorphanol IVRLP. The only other study to
assess MNT changes in horses following use of a tourniquet was the previously cited
Colbath et al. (2016) IVRLP study, and they did not appreciate this pattern of decreased
MNTs in the treated limb.40 However, their last MNT testing was performed immediately
after tourniquet removal which, assuming a similar pattern of response occurred, would
not have captured this effect, given it was not seen until the tourniquet had been off for
30 minutes.40 Thus, further research into the effect of tourniquet application and release
on MNTs in horses is warranted. Additionally, any future analgesic IVRLP investigations
planning to use similar methodology should also place a tourniquet on the control limb to
mitigate this potential confounding factor.
All horses were monitored closely for evidence of significant local or systemic
side-effects associated with the butorphanol IVRLP. With respect to local effects
associated with the perfusion itself, some mild swelling was seen at the sampling and
injection sites for one to two days post-procedure but resolved with conservative
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management. Such mild local responses are typical for these procedures and considered
unlikely to be due to the specific use of butorphanol.42 Due to concerns regarding
gastrointestinal sequelae from opioid use, routine physical exams and quantification of
manure output were used to subjectively assess for signs of abdominal discomfort or
slowed gastrointestinal transit. The vital parameters of all horses remained within normal
limits for the duration of the study period, none exhibited inappetance or signs of
abdominal discomfort, and manure output remained consistent for each horse throughout
the study. The addition of a motility marker, such as feeding inert beads, would have
offered an opportunity to more objectively characterize the rate of passage of manure and
thus any significant changes in motility. An inherent limitation of the present study,
however, was the potential for a confounding effect of sedation. Decreased
gastrointestinal motility following administration of alpha-adrenergic agonist drugs such
as detomidine is well documented.11,34 As IVRLP necessitates the use of a sedative, the
additional expense of incorporating some form of rate of passage indicator for the present
pilot project was deemed unjustified. However, this may be considered for follow-up
studies, particularly if different opioid IVRLPs are to be compared.
There are some important considerations regarding clinical utility of this IVRLP
protocol. It should be noted that the horses used in the study were sedated with only an
alpha-2 agonist for the IVRLP. As practitioners may routinely use a sedation protocol
including both an alpha-2 agonist and an opioid, it is advisable to consider the total horse
dose in these cases. Based on the present study, no comment can be made with respect to
the systemic effects of both a systemically-administered sedative dose and a local dose
delivered by IVRLP. A further consideration that requires evaluation prior to clinical use
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is whether there is a reduction in either antimicrobial or analgesic efficacy when opioids
are combined with an antimicrobial for IVRLP. This has been previously evaluated with
respect to local anesthetics, and the same should be pursued for opioids, as IVRLP offers
an appealing opportunity for easy simultaneous local delivery of both therapies.40,41
Limitations
The present study has several limitations. Firstly, one of the six horses studied had
no butorphanol detected in synovial fluid at any time point. Review of perfusion
technique, perfusion recordings and serum values did not reveal a clear cause for this
perfusion failure. The unfortunate loss of the data from this horse contributed to the
limited conclusions that could be drawn from the study. A second limitation was that the
horses used were clinically normal, limiting the direct translation of findings to diseased
or surgical patients. It has been reported that drug delivery and opioid receptor activity is
altered in septic, traumatized or otherwise abnormal tissues, which may result in higher
drug concentrations and efficacy following IVRLP.14,41,44,75 Additionally, nociceptive
thresholds and responses to analgesics may be markedly different in healthy horses
versus those with a painful limb condition.55 Future studies should be pursued to tease
apart the implications of tissue damage on the therapeutic efficacy of analgesic IVRLP.
The ultimate limitation of this study was the small sample size, which limited the power
of the study to make specific comparisons between MNTs of control and treated limbs, as
well as with respect to site of limb stimulation and specific intra-synovial concentrations
that resulted in effective analgesia. The study was designed primarily as a proof-ofconcept project to lay the groundwork for objective assessment of analgesic IVRLP
efficacy and, as such, a small sample size was used. Two pilot horses were used to test
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the planned procedure prior to the present project and the concentrations achieved in
these horses were much less variable, suggesting the planned six horses would be
sufficient. As the sampling was performed differently in these horses, this data was not
included in the main study due to a desire for consistency. Unfortunately, due to the loss
of one set of data and the variability in the synovial concentrations achieved, the sample
size was ultimately insufficient. Given the expected degree of variability and the
possibility of perfusion failures, future investigations with a larger sample size may allow
for stronger statistical analyses and conclusions regarding the use of butorphanol IVRLP.
Conclusions
The present study is a useful addition to the evaluation of opioids for use as a
regional analgesic therapy. The procedure appears, subjectively, to be well tolerated both
locally and systemically at the butorphanol dosage used. The MNT data provides the first
step towards evaluating the analgesia provided by an opioid IVRLP and further MNT
research should be pursued to determine what synovial and tissue concentrations of
butorphanol would be of clinical benefit.
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